July 2025 in “Skin Appendage Disorders” Dutasteride microinfusion and microneedling both effectively treat male hair loss.
July 2004 in “Current Urology Reports” 31 citations
,
January 1989 in “The Prostate/The prostate” Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
20 citations
,
January 2004 in “PubMed Central” 5α-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT levels.
24 citations
,
September 2002 in “Der Urologe” A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.
25 citations
,
June 2002 in “Steroids” 4-azasteroids, including finasteride, can inhibit 5α-reductase, helping treat conditions like enlarged prostate and hair loss.
22 citations
,
May 2003 in “Planta Medica” Torilin from Torilis japonica can inhibit testosterone 5α-reductase but is less effective than finasteride.
November 2024 in “Nanomaterials” The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.
April 2023 in “Journal of Investigative Dermatology” A new treatment for hair loss shows promise with fewer side effects.
January 2009 in “프로그램북(구 초록집)” 184 citations
,
January 2000 in “European Urology” Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
October 2021 in “European urology open science”
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
June 2022 in “Journal of The European Academy of Dermatology and Venereology” Microneedling with topical dutasteride improves hair growth in men with hair loss and is safe to use.
September 2017 in “ics.org” 1 citations
,
April 1999 in “The Journal of Urology”
35 citations
,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
1 citations
,
October 2020 in “Current Drug Discovery Technologies” The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.
5 citations
,
January 2020 in “Skin appendage disorders” Oral dutasteride works better for hair loss, but has more sexual side effects; intralesional dutasteride is a possible alternative.
August 2004 in “Medisch-Farmaceutische Mededelingen” Long-term use of finasteride may cause breast cancer in men.
December 2025 in “JMIR Dermatology” Topical finasteride is well-tolerated and satisfies most users with minimal side effects.
August 2023 in “Frontiers in Oncology” New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
5 citations
,
February 1997 in “Bioorganic & Medicinal Chemistry” New compounds were made that effectively block a specific enzyme related to androgen conditions.
23 citations
,
July 1993 in “Pharmacotherapy” Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.
February 2026 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
January 2018 in “Journal of analytical, bioanalytical and separation techniques”
September 2019 in “Journal of Investigative Dermatology” Finasteride treatment lowers urine androgen and prostaglandin levels, making them potential markers for effectiveness.